Selection bias in Andes et al

Clinical Infectious Diseases

Volumn 55, Issue 6, 2012, Pages 893-894

  Cisneros, J M ^a   Neth, O ^a   Pachon J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; FLUCONAZOLE;

CANDIDEMIA; EPIDEMIOLOGY; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LETTER; MORTALITY; MYCOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; FEMALE; HUMANS; MALE;

EID: 84865446831     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis524     Document Type: Letter

References (5)

1. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110-22.
2. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-40. (Pubitemid 46233255)
3. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519-27. (Pubitemid 46670281)
4. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-82. (Pubitemid 46919773)
5. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-9. (Pubitemid 35461658)